Swedbank AB Has $44.70 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Swedbank AB decreased its stake in Illumina, Inc. (NASDAQ:ILMN) by 23.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 334,517 shares of the life sciences company’s stock after selling 101,359 shares during the quarter. Swedbank AB owned approximately 0.21% of Illumina worth $44,702,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Versant Capital Management Inc boosted its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Private Trust Co. NA boosted its stake in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc acquired a new position in Illumina in the third quarter worth $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 1.4 %

NASDAQ:ILMN opened at $131.72 on Thursday. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a market cap of $20.89 billion, a price-to-earnings ratio of -13.22 and a beta of 1.11. The stock has a 50-day moving average price of $139.05 and a two-hundred day moving average price of $135.07.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the previous year, the firm earned $0.33 earnings per share. The company’s revenue was down 3.5% on a year-over-year basis. As a group, equities analysts expect that Illumina, Inc. will post 4.13 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ILMN shares. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. TD Cowen boosted their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. UBS Group boosted their target price on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and an average target price of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.